Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Earnings Per Share Diluted of $1.44 (loss) per share for the year ending 2025.
- RECURSION PHARMACEUTICALS, INC. showed an increase of +14.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.85 (loss) per share | Q2 2020: $0.88 (loss) per share | Q3 2020: $1.09 (loss) per share | Q1 2021: $1.33 (loss) per share | Q2 2021: $0.31 (loss) per share | Q3 2021: $0.28 (loss) per share | Q1 2022: $0.33 (loss) per share | Q2 2022: $0.38 (loss) per share | Q3 2022: $0.35 (loss) per share | Q1 2023: $0.34 (loss) per share | Q2 2023: $0.38 (loss) per share | Q3 2023: $0.43 (loss) per share | Q1 2024: $0.39 (loss) per share | Q2 2024: $0.40 (loss) per share | Q3 2024: $0.34 (loss) per share | Q1 2025: $0.50 (loss) per share | Q2 2025: $0.41 (loss) per share | Q3 2025: $0.36 (loss) per share.
- Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Earnings Per Share Diluted has grown by 49.8%.
- Historical annual values: Fiscal year 2025: $1.44 (loss) per share | Fiscal year 2024: $1.69 (loss) per share | Fiscal year 2023: $1.58 (loss) per share | Fiscal year 2022: $1.36 (loss) per share | Fiscal year 2021: $1.49 (loss) per share | Fiscal year 2020: $3.99 (loss) per share | Fiscal year 2019: $2.87 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: